Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 3/20 | 0.64 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA4 | P22748 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762649 | 0.98 | BDKRB1 (0.67) | BDKRB1CA12CA1CA2CA4 | |
| SCHEMBL6762747 | 0.94 | BDKRB1 (0.63) | BDKRB1CA12CA1CA2CA4 | |
| SCHEMBL6760074 | 0.94 | BDKRB1 (0.65) | BDKRB1CA12CA1CA2CA4 | |
| SCHEMBL6761595 | 0.94 | BDKRB1 (0.63) | BDKRB1CA12CA1CA2CA4 | |
| SCHEMBL6761698 | 0.90 | BDKRB1 (0.77) | BDKRB1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL6761805 | 0.90 | BDKRB1 (0.81) | BDKRB1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL6761675 | 0.89 | BDKRB1 (0.56) | BDKRB1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL6760095 | 0.89 | BDKRB1 (0.73) | BDKRB1LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL6766772 | 0.88 | BDKRB1 (0.81) | BDKRB1CA12CA1CA2CA4 | |
| SCHEMBL6981011 | 0.87 | BDKRB1 (0.78) | BDKRB1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | BDKRB1 481/4885CA12 3089/4885CA1 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.